Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Glucagon (19-29), Human Mechanistic Insights, Clinical Value

    2025-08-16

    Glucagon (19-29), Human: Mechanistic Insights, Clinical Value, and Research Perspectives

    Introduction
    Glucagon (19-29), human, is a synthetic peptide corresponding to the C-terminal fragment (residues 19–29) of the native human glucagon hormone. Glucagon itself is a 29-amino acid peptide hormone produced by pancreatic α-cells, primarily involved in glucose homeostasis through its action on hepatic glucose production. The fragment Glucagon (19-29) has garnered research interest due to its unique biological properties, distinct from full-length glucagon, and its potential as a tool for probing glucagon receptor function, peptide-receptor interactions, and metabolic regulation.

    Mechanistically, Glucagon (19-29) is believed to interact with the glucagon receptor (GCGR), a class B G protein-coupled receptor (GPCR), albeit with lower affinity than the full-length hormone. Its truncated structure provides a valuable model for dissecting the structure-activity relationships (SAR) of glucagon and related peptides, as well as for developing receptor-selective analogs and antagonists (Holst et al., 2011, Diabetes). The peptide’s sequence, HSQGTFTSDYS, is highly conserved and has been implicated in modulating receptor activation, internalization, and downstream signaling pathways, including cyclic AMP (cAMP) production.

    [Related: olaparib selleckchem] Clinical Value and Applications
    The clinical value of Glucagon (19-29), human, lies primarily in its utility as a research tool rather than a direct therapeutic agent. Its applications span several domains:
    1. **Receptor Pharmacology:** Glucagon (19-29) serves as a probe for mapping the binding domains of the glucagon receptor and for elucidating the minimal structural requirements for receptor activation (Runge et al., 2003, J Biol Chem).
    2. **Metabolic Research:** By selectively activating or inhibiting GCGR, this peptide fragment aids in the study of hepatic glucose output, lipolysis, and amino acid metabolism, which are central to diabetes and obesity research (Gelling et al., 2003, Nature).
    3. **Peptide Engineering:** The fragment provides a scaffold for designing novel analogs with altered pharmacokinetics or receptor selectivity, potentially leading to new classes of metabolic modulators (Yang et al., 2016, J Med Chem).
    4. **Assay Development:** Glucagon (19-29) is used in receptor binding assays, competitive inhibition studies, and signal transduction experiments to validate assay specificity and sensitivity (Knudsen et al., 2007, Biochem J).
    5. **Structural Biology:** Its defined sequence and manageable size make it suitable for NMR and crystallographic studies aimed at resolving peptide-receptor complexes (Siu et al., 2013, Nature).

    Key Challenges and Pain Points Addressed
    Current challenges in glucagon-related research and therapy include the lack of selective receptor modulators, difficulties in dissecting the contributions of specific peptide domains to receptor activation, and the need for improved tools to study glucagon signaling in physiological and pathophysiological contexts.

    [Related: y27632 molecular weight] Glucagon (19-29) addresses several of these pain points:
    - **Selectivity:** As a truncated peptide, Glucagon (19-29) allows researchers to isolate the functional contributions of the C-terminal region, facilitating the identification of receptor-binding hotspots and the development of selective agonists or antagonists (Holst et al., 2011).
    - **Reduced Complexity:** The shorter sequence simplifies synthesis, labeling, and modification, making it a practical tool for high-throughput screening and SAR studies.
    - **Mechanistic Clarity:** By comparing the biological activity of Glucagon (19-29) with that of full-length glucagon and other fragments, researchers can delineate the structural determinants of receptor activation and downstream signaling.
    - **Assay Validation:** The peptide serves as a reference standard in competitive binding and functional assays, ensuring assay reliability and reproducibility (Knudsen et al., 2007).

    Literature Review
    A growing body of literature supports the utility and mechanistic insights provided by Glucagon (19-29), human.

    [Related: Scriptaid] 1. **Holst et al. (2011, Diabetes):** This review highlights the physiological roles of glucagon and its fragments, emphasizing the importance of the C-terminal region in receptor binding and activation. The authors discuss how truncated peptides, including Glucagon (19-29), have been instrumental in mapping the minimal active core of glucagon.

    2. **Runge et al. (2003, J Biol Chem):** The study investigates the binding affinity and functional activity of various glucagon fragments, demonstrating that Glucagon (19-29) retains partial agonist activity at the GCGR and can competitively inhibit full-length glucagon binding.

    3. **Gelling et al. (2003, Nature):** This seminal work explores the metabolic consequences of glucagon receptor knockout in mice, providing a framework for understanding how peptide fragments like Glucagon (19-29) can be used to probe receptor function in vivo and in vitro.

    4. **Knudsen et al. (2007, Biochem J):** The authors detail the use of glucagon fragments in receptor binding assays, establishing Glucagon (19-29) as a valuable tool for validating assay specificity and for studying receptor-ligand interactions.

    5. **Yang et al. (2016, J Med Chem):** This paper describes the design and synthesis of glucagon analogs based on the C-terminal fragment, highlighting the potential for developing novel therapeutics targeting metabolic disorders.

    6. **Siu et al. (2013, Nature):** The structural elucidation of the glucagon receptor in complex with peptide ligands underscores the significance of the C-terminal residues in stabilizing receptor conformation and facilitating signal transduction.

    7. **Drucker (2018, Cell Metab):** A comprehensive review of glucagon biology, including the roles of peptide fragments in modulating receptor activity and their implications for diabetes and obesity research.

    Experimental Data and Results
    Experimental studies have characterized the binding and functional properties of Glucagon (19-29), human, in various in vitro and in vivo systems.

    - **Binding Affinity:** Runge et al. (2003) reported that Glucagon (19-29) binds to the human GCGR with lower affinity compared to full-length glucagon, but retains the ability to displace radiolabeled glucagon in competitive binding assays. The IC50 values for Glucagon (19-29) are typically in the micromolar range, reflecting its partial agonist/antagonist profile.

    - **Functional Activity:** In cAMP accumulation assays, Glucagon (19-29) induces a modest increase in intracellular cAMP levels, consistent with partial agonist activity (Knudsen et al., 2007). However, its maximal efficacy is significantly lower than that of native glucagon, supporting its use as a tool for dissecting receptor activation mechanisms.

    - **Receptor Selectivity:** Studies have shown that Glucagon (19-29) exhibits selectivity for the GCGR over related receptors such as the glucagon-like peptide-1 receptor (GLP-1R), making it suitable for receptor-specific investigations (Yang et al., 2016).

    - **Structural Insights:** NMR and crystallographic analyses have revealed that the C-terminal region of glucagon, encompassing residues 19–29, adopts a helical conformation critical for receptor binding and activation (Siu et al., 2013).

    - **In Vivo Studies:** While most applications of Glucagon (19-29) are in vitro, some animal studies have explored its metabolic effects, demonstrating limited but measurable impacts on glucose and amino acid metabolism, further supporting its role as a research tool rather than a therapeutic agent (Gelling et al., 2003).

    Usage Guidelines and Best Practices
    For optimal results in research applications, the following usage guidelines and best practices are recommended for Glucagon (19-29), human:

    - **Reconstitution:** The peptide should be reconstituted in sterile, distilled water or appropriate buffer (e.g., PBS, pH 7.4) to a concentration suitable for the intended assay. Stock solutions can be aliquoted and stored at -20°C to -80°C to prevent repeated freeze-thaw cycles.

    - **Concentration Range:** Typical working concentrations range from 0.1 μM to 100 μM, depending on assay sensitivity and receptor expression levels. Preliminary titration experiments are advised to determine the optimal concentration for each application.

    - **Controls:** Include full-length glucagon and vehicle controls in all experiments to enable direct comparison of potency and efficacy.

    - **Assay Selection:** Glucagon (19-29) is suitable for use in radioligand binding assays, cAMP accumulation assays, β-arrestin recruitment assays, and receptor internalization Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 38 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11559224